Skip to main content

CNRT and IBA sign collaboration agreement to install a Cyclone® IKON in China

Jiming Cai, General Manager of CNRT; Chen Li,  IBA Radio Pharma Solutions Sales VP China

Tuesday, August 30, 2022 - 10:02

<p><span><span><span><span><em><span lang="EN-US"><span><strong>The Cyclone<sup>®</sup> IKON is IBA’s </strong></span></span></em><strong><em><span lang="EN-US"><span>new high energy and high-capacity cyclotron</span></span></em><em> </em><em><span lang="EN-US"><span>which offers the largest energy spectrum for PET and SPECT isotopes from 13 MeV to 30 MeV</span></span></em></strong></span></span></span></span></p> <p><span><span><span><span><strong><span lang="EN-US"><span><span>Louvain-La-Neuve, Belgium, August 30, 2022 –</span></span></span></strong><a href="https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fiba-worldwide.com%2F&amp;data=05%7C01%7CPapsyM%40baptisthealth.net%7C3797299bc8734dfd571408da3f62ade2%7C3783f79319c8492899c48d1861e6cc1f%7C0%7C0%7C637891990358885904%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=bkvd0R74ByW6nD83M0EQJt0FCrXk6Q9LEEXbSgiqxkI%3D&amp;reserved=0"><span><span>IBA</span></span></a><span lang="EN-US"><span><span>(Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, announced it has</span></span></span><span lang="EN-US"><span> signed a collaboration agreement<span> with </span>Chengdu New Radiomedicine Technology Co., Ltd (CNRT)</span></span> <span lang="EN-US"><span><span>to install a <a href="https://www.iba-radiopharmasolutions.com/cyclone-ikon">Cyclone<sup>®</sup> IKON</a> in Chengdu, Sichuan Province, China. CNRT is a Chinese manufacturer and provider of medical isotopes used for oncology diagnosis and therapy. The typical end-user price for a Cyclone® IKON solution is between EUR 15 and 20 million.</span></span></span></span></span></span></span></p> <p><span><span><span><span><span lang="EN-US"><span>The <a href="https://www.iba-radiopharmasolutions.com/cyclone-ikon">Cyclone<sup>®</sup> IKON</a> will be used for the production of novel isotopes for use in theranostics and targeted therapies, particularly for Germanium-68 (used for Germanium-68/Gallium-68 generators), Iodine-123 and other radioisotopes such as Copper-64. These enable</span></span><span lang="EN-US"><span> the administration of radiation directly to the targeted cells, with minimal toxic side effects to surrounding healthy cells, unlike traditional modalities. </span></span></span></span></span></span></p> <p><span><span><span><span><strong><span lang="EN-US"><span>Jiming Cai, General Manager of CNRT, commented</span></span></strong><span lang="EN-US"><span>: “<em>We are pleased to be working with IBA to develop a stable and independent supply of commonly used medical isotopes. This will be the first <a href="https://www.iba-radiopharmasolutions.com/cyclone-ikon">Cyclone<sup>®</sup> IKON</a> cyclotron system to be installed by IBA in China for the production of multiple radioisotopes, and is expected to be fully operational by 2025. In due course CNRT will be able to provide high-quality and efficient medical isotopes to our clients.”</em></span></span></span></span></span></span></p> <p>&nbsp;</p> <p><span><span><span><span><strong><span lang="EN-US"><span>Bruno Scutnaire, President of IBA RadioPharma Solutions, added</span></span></strong><span lang="EN-US"><span>: <em>“There are a growing number of clinical trials and an increase in new radiotherapeutic molecule developments, with many companies recognizing the great potential of theranostics. Since its launch in 2020, this is the fourth <a href="https://www.iba-radiopharmasolutions.com/cyclone-ikon">Cyclone<sup>®</sup> IKON</a> unit sold globally and we look forward to working with CNRT over the coming months and years.”</em> </span></span></span></span></span></span></p> <p>&nbsp;</p> <p><span><span><span><strong><span lang="EN-US"><span>About CNRT</span></span></strong></span></span></span></p> <p><span><span><span><span><span lang="EN-US"><span>Chengdu New Radiomedicine Technology Co., Ltd. was established in the year 2016. It is a high-tech enterprise integrating Research and development of radiopharmaceuticals, innovation and industrialization, engaged in research, production and sales of medical isotopes, carry out demonstration research on the diagnosis and treatment of a variety of malignant tumor diseases, provide nuclear medicine technical services and scientific and technological consulting, etc. The company has built up an advanced radiopharmaceutical testing and research platform, an advanced radioactive pharmacology research platform, and an advanced radiopharmaceutical industrialization innovation platform. CNRT will ensure continuously provide high-quality, High efficiency and affordable radioactive diagnosis and treatment drugs for the patients, provide high-quality medical isotope nuclide products for the radiopharmaceutical industry, through technology, concept and products innovation.</span></span></span></span></span></span></p> <p><span><span><span><strong><span lang="EN-US"><span>About IBA</span></span></strong></span></span></span></p> <p><span><span><span><span><span lang="EN-US"><span>IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,600 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.</span></span></span></span></span></span></p> <p><span><span><span><span><span lang="EN-US"><span>IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).</span></span></span></span></span></span></p> <p><span><span><span><span><span lang="EN-US"><span><span>More information can be found at: </span></span></span><a href="http://www.iba-worldwide.com"><span><span><span>www.iba-worldwide.com</span></span></span></a></span></span></span></span></p> <p>&nbsp;</p> <p><span><span><span><span><strong><span><span><span>CONTACTS</span></span></span></strong></span></span></span></span></p> <p><span><span><span><span><strong><span><span>Soumya Chandramouli</span></span></strong></span></span></span></span></p> <p><span><span><span><span><strong><span><span>Chief Financial Officer</span></span></strong></span></span></span></span></p> <p><span><span><span><span><span><span>+32 10 475 890</span></span></span></span></span></span></p> <p><span><span><span><span><a href="mailto:Investorrelations@iba-group.com"><span lang="FR-BE"><span>Investorrelations@iba-group.com</span></span></a></span></span></span></span></p> <p>&nbsp;</p> <p><span><span><span><span><strong><span><span>Olivier Lechien</span></span></strong></span></span></span></span></p> <p><span><span><span><span><span lang="EN-US"><span>Corporate Communication Director</span></span></span></span></span></span></p> <p><span><span><span><span><span lang="EN-US"><span>+32 10 475 890</span></span></span></span></span></span></p> <p><span><span><span><span><a href="mailto:communication@iba-group.com"><span><span>communication@iba-group.com</span></span></a></span></span></span></span></p> <p>&nbsp;</p> <p><span><span><span><span><span><strong><span lang="EN-US"><span><span>Consilium Strategic Communications</span></span></span></strong></span></span></span></span></span></p> <p><span><span><span><span><span><span lang="EN-US"><span><span>Amber Fennell, Angela Gray, Lucy Featherstone</span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><span lang="EN-US"><span><span>+44 (0) 20 3709 5700</span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span><a href="mailto:IBA@consilium-comms.com"><span><span><span>IBA@consilium-comms.com</span></span></span></a></span></span></span></span></span></p> Read Full Press Release FR  
Read Full Press Release EN  
Share

More news

IBA et SCK CEN lancent Pantera

IBA et SCK CEN lancent Pantera, joint-venture pour la production d'actinium-225

Louvain-la-Neuve, Belgique, le 22 septembre 2022 - IBA (Ion Beam Applications S.A.), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, et le Centre de recherche nucléaire belge SCK CEN ont annoncé aujourd'hui le nom de leur coentreprise&nbsp;: Pantera SA/NV, dont elles sont convaincues qu’elle apportera de nouvelles perspectives aux patients atteints de cancer. Comme indiqué l’année dernière lors de l'annonce du partenariat stratégique de Recherche &amp; Développement (R&amp;D), cette nouvelle société aura pour objectif d’assurer la production à grande échelle d'Actinium-225 (225Ac), l'un des radioisotopes à émission alpha les plus prometteurs pour combattre les cancers. En travaillant à cette production à grande échelle, l'objectif de Pantera est d'améliorer l'accessibilité d'une future thérapie innovante contre le cancer basée sur l’ 225Ac. &nbsp; La complémentarité des expertises d'IBA et de SCK CEN a été démontrée par le travail exhaustif de R&amp;D mené au cours de l’année écoulée en vue d’être en mesure de produire de grands volumes d’ 225Ac. Pantera achève actuellement les études de faisabilité technique qui lui permettront ensuite de commencer&nbsp; la construction de sa première installation à Mol, en Belgique. Les premiers travaux de cette installation devraient commencer en 2024 pour un début de la production en 2027. &nbsp; Sven Van den Berghe, ancien directeur de l'Institut des sciences des matériaux nucléaires au SCK CEN, a été nommé Chief Executive Officer (CEO), et Samy Bertrand, ancien responsable technique des applications théranostiques chez IBA, prend le poste de Chief Technical Officer (CTO). &nbsp; Bruno Scutnaire, Président d'IBA RadioPharma Solutions et Président du Conseil d'Administration de Pantera, a déclaré : «&nbsp;L'actinium-225 est très prometteur pour le traitement d'une grande variété de cancers, mais seule une très petite quantité de cet isotope est disponible dans le monde aujourd'hui.&nbsp; Une fois que les traitements contre le cancer basés sur le 225Ac seront approuvés, Pantera sera à même de fournir un approvisionnement fiable de cet isotope prometteur.&nbsp;» &nbsp; Peter Baeten, directeur général adjoint du SCK CEN et membre du conseil d'administration de Pantera, a commenté : «&nbsp;Lancer Pantera était un choix logique pour le SCK CEN et IBA, qui permet à ce joint-venture de tirer parti des capacités d'innovation des deux organisations, tout en s’appuyant sur l’agilité d'une startup. Cette autonomie est nécessaire dans ce domaine qui évolue rapidement.&nbsp;» &nbsp; Sven Van den Berghe, nommé Chief Executive Officer de Pantera, a ajouté : «&nbsp;Je suis enthousiaste à l'idée de contribuer à réaliser la mission de Pantera&nbsp;: apporter un nouvel espoir aux patients atteints de cancer en rendant accessible l'utilisation de radioisotopes, comme base de nouveaux produits radiopharmaceutiques, tels que l'actinium-225. Pantera offre de nouveaux horizons, et amène potentiellement une option de traitement efficace tout en maximisant la qualité de vie des patients.&nbsp;» &nbsp; L'actinium-225 possède le grand potentiel de traiter plus efficacement les cancers. Les premiers résultats montrent que ce radioisotope théranostique élimine complètement les cellules cancéreuses, au lieu de se contenter d'inhiber la croissance des tumeurs. Le risque de récidive semble également diminuer. À ce jour, des recherches approfondies et de nombreuses études sont en cours et visent à la fois les cancers à forte prévalence, notamment les cancers de la prostate, du poumon, du côlon, du sein, du pancréas, du sang (leucémie et autres formes rares) et du rein, mais aussi à des formes plus rares de cancers comme le glioblastome, la forme la plus mortelle d'un cancer du cerveau très invasif. &nbsp; &nbsp;
See more